Three sets of neutralizing monoclonal antibodies (MAbs) used to type the outer capsid protein VP7 of four group A rotavirus serotypes (1 through 4) were compared in competition immunoassays. Reciprocal competition was observed for each of the VP7 type 2-, 3-, and 4-specific MAbs. The VP7 type 1 MAbs exhibited variable competition patterns with other VP7 type 1 MAbs. MAb RV4:3, which has been used to recognize antigenic variants within VP7 type 1 strains, showed reciprocal competition with the four VP7 type 3 MAbs (RV3:1, YO-lE2, 4F8, and 159) using a VP7 type 3 virus (SAll) as antigen. MAb 2C9, also prepared against VP7 type 1, reacted with VP7 type 3 strains and competed with a VP7 type 3 MAb, 159, using RRV as antigen. Use of the different sets of VP7 type-specific MAbs in the enzyme-linked immunosorbent assay permitted the recognition of six antigenic variants within VP7 types 1, 2, and 3 among specimens whose VP7 type could not be determined previously with only one set of typing MAbs. These results demonstrate differences of typing ability among these VP7-specific MAbs and emphasize the need to improve the sensitivity of typing systems by incorporating panels of MAbs reacting with several neutralizing epitopes.
Rotaviruses are the most commonly recognized cause of gastroenteritis in children worldwide (9, 19) . Rotaviruses have two surface structural proteins, VP4 and VP7, which generate neutralizing antibodies (16, 18, 19, 26, 27) . VP7 is the major determinant of serotype specificity (7) . Several investigators have prepared serotype-specific neutralizing monoclonal antibodies (MAbs) to VP7 and incorporated these MAbs into typing enzyme-linked immunosorbent assays (ELISAs) to describe the antigenic diversity of circulating rotaviruses (4, 17, 23, 30, 33, 35, 36) .
We are interested in understanding the antigenic diversity of circulating rotaviruses, as well as the immune response to antigenic variants. In this study, we compared the three most widely used sets of neutralizing VP7-typing MAbs for their abilities to bind rotavirus particles in competition immunoassays. These panels of MAbs already have been shown to bind differently to sets of circulating human rotaviruses in typing ELISAs (11, 23, 25, 35, 36) . Some neutralizing MAbs bind only a subset of viruses (called monotypic variants) within a VP7 type in ELISAs (4, 10) . The apparent natural antigenic diversity of circulating rotaviruses has made it questionable whether only one set of suitable reagents can be applied as a standard set of typing MAbs worldwide. Some of the MAbs have been used to measure epitope-and VP7 type-specific antibody responses in vaccine recipients (15, 29) . One method for selecting typing MAbs would be to choose MAbs that bind to different sites on VP7. Unfortunately, the mutation site of the gene encoding VP7 in viral variants that escape neutralization by type-specific neutralizing MAbs is known for only some MAbs (6, 22, 31, 32 ) (see Table 1 ). We used direct comparisons of the MAbs in competition assays to help improve the selection of MAb sets for typing assays, for studies of the * Corresponding author.
range of antigenic subtypes circulating in epidemiological surveys, and for the investigation of epitopes involved in protective immunity.
MATERUILS AND METHODS
Virus production and purification. Both laboratory strains and virus from clinical specimens were used as antigen in the competition assays. Cultivatable virus strains included human Wa (serotype 1); human S2 (serotype 2); simian SAl1 and RRV; human YO, Ito, and P (serotype 3); and human St. Thomas 3 (serotype 4) (20) . These viruses were propagated in MA-104 cells in the presence of pancreatin as previously described (8, 20) . Each antigen was diluted in the competition assay with homotypic MAb reagents to yield an absorbance 50% of maximal, which was in the range of 0.4 to 0.8 at 414 nm. Because MAb RV4:1 bound the prototype VP7 type 1 virus Wa poorly, for competition assays with MAb RV4:1, three clinical specimens from the year 1989, from the same site (23) , and showing the same reactivity pattern with all six VP7 type 1 MAbs were pooled in equal volume to obtain a sufficient quantity of antigen.
Competitive MAb capture ELISA. The competition ELISA was performed as described previously (1) with minor modifications. Three sets of neutralizing MAbs (purified or ascites), RV4:1, RV4:2, RV4:3, RV5:3, RV3:1, and ST3:1; KU-4, S2-2G10, YO-lE2, and ST-2G7; and 5E8, 2C9, IC10, 4F8, and 159, specific for the rotavirus outer capsid protein VP7 of serotypes 1 through 4, were tested (Table 1) . We found that all the MAbs could be used as both capture and detector reagents in the competition assay, even though some of these MAbs had been reported previously to be more sensitive or effective (in serotyping tests) as detector antibodies (4) . MAb 60-F2D4 was included in the competition assays for comparison because it reacts with a VP7 epitope present on most rotavirus strains (28 
RESULTS
Competition of MAbs prepared against different VP7 types. Our initial assays showed that, with the exception of MAbs RV4:3 and 2C9, none of the MAbs tested bound to standard laboratory strains outside the VP7 type against which they were prepared. To confirm that MAb binding in the competition assays showed the same specificity as in the VP7-typing ELISA (23), we performed cross-competition assays among the serotype 1-to 4-specific typing MAbs KU-4, S2-2G10, YO-1E2, and ST-2G7, respectively. As expected, only homotypic competition was observed ( (Fig. 1) . KU-4's competition with MAbs RV4:3, 5E8, and 2C9 was consistently less than 50%. This result was observed whether the pool of clinical isolates or Wa was used as antigen. RV4:1 and RV4:2 were unlike KU-4 in that both competed with RV4:3, 2C9, and 5E8 ( Fig. 1 and 2 ; Table 2 ). This indicated that the VP7 type 1 MAbs might be grouped as follows: RV4:1 with RV4:2; RV4:3 with 2C9 and 5E8; and KU-4 by itself. However, 2C9 differentiated RV4:1 from RV4:2 by competing with RV4:1 partially but competing with RV4:2 fully (80%). RV4:1 also differed from RV4:2 because RV4:1 reacted poorly with VP7 type 1 strain Wa, whereas RV4:2 reacted strongly with this strain. Finally, differences among MAbs RV4:3, 2C9, and 5E8 were noted. MAbs RV4:3 and 2C9 bound VP7 type 3 viruses and RV4:3 competed with type 3-specific MAbs, whereas 5E8 did neither (see below). In summary, then, among the six VP7 type 1 MAbs evaluated, only RV4:3 and 2C9 exhibited similar patterns of competition.
Competition (12, 25) . Because competition assays require only the binding properties of the immunoglobulin, experiments can be conducted with neutralizing as well as nonneutralizing MAbs.
The competition results suggest that the type-specific epitopes cluster together. For VP7 type 3, the ninth genes of neutralization escape mutants to MAbs RV3:1, YO-lE2, 4F8, and 159 have been sequenced, and mutations induced by the MAbs have been found at amino acids 211, 221, 96, and 94, respectively (Table 2) (6, 22, 24) . The first two sites are located within region C and the latter two sites are located within region A of VP7 (6) . The finding of complete competition among these MAbs would support previous reports (6) that regions A and C are adjacent to each other on the particle although separated in the linear amino acid sequence. Others have reported nonreciprocal competition between VP7 type 3 MAbs 159 and 4F8 with RRV as antigen (31) . Sufficient MAb mapping information for MAbs to VP7 type 2 and type 4 is not available for us to comment upon spatial localization of the binding epitopes of these MAbs.
We observed partial or one-way competition among the VP7 type 1 MAbs as well as for a number of the VP7-typing MAbs with the VP7 common MAb. Differences in MAb affinity sometimes can explain such reactions. If the concentrations of each MAb needed to obtain the optimal binding of antigen reflected differences in the binding affinity (Table 2) , then the partial and one-way competition observed with RV4:3 and KU-4 (and that observed with the VP7 common 60-F2D4 and several other MAbs) may have been due to differences in binding affinity. Minor differences in the degree of competition in some instances may also correlate with known differences in the gene sequence for VP7. For example, we failed to observe reciprocal competition between VP7 type 1 MAb KU-4 and MAbs RV4:3, 2C9, and 5E8. For the pair KU-4 and 2C9, competition with Wa antigen was virtually complete (95%) in one direction; in the other direction, competition was partial (40%). This result contrasts with that of others who have reported reciprocal competition between KU-4 and 2C9 (15) . The difference between our results and those of Green et al. may be due simply to differences in the interpretation of competition curves. Our result, that competition between these MAbs is one way, is supported by mapping data; KU-4 induces mutations which map to amino acid 213 (region C) (32), whereas 2C9 induces mutations which map to amino acid 94 (region A) (14) . Also, reciprocal competition between KU-4 and RV4:2 was observed, and both induce mutations at residue 213 (2b) .
Partial competition (47%) between 2C9 (region A) and RV4:1 (region B) again was observed when 2C9 was used as the competing antibody. This observation confirms that the variable regions A, B, and C are closely related to one another (21) . Region A previously has been shown to be close to region C (6). The possibility that region B is adjacent to both region A and region C is supported by the observation that competition between RV4:1 (region B) and another MAb that appears to map to region A (RV4:3) was reciprocal, as was competition between RV4:1 and MAbs RV4:2 and KU-4, which appear to map to region C. Another MAb which appears to map to region B (6) has not been used in competition assays.
Changes in amino acid sequence also may explain observed differences in MAb binding at the same site. MAb RV4:1, produced against serotype 1 strain RV4, induces mutations at residue 147 of region B and reacted weakly with the serotype 1 virus strain Wa. The amino acid sequences of Wa and RV4 are similar in region B except that Wa contains a serine at position 147 rather than an asparagine. Among all VP7 type 2 human rotaviruses, aspartic acid is conserved at position 190, while in VP7 type 1, 3, or 4, this position is occupied by serine (13) . VP7 type 2 MAb S2-2G10 is type specific (33) , and it has been mapped to amino acid site 190 (12) . (25) . On the other hand, YO-lE2 proved to be a suitable reagent for VP7 type 3 detection in samples from Japan (35) , Houston, and elsewhere in the United States (11, 23) . Naturally occurring VP7 type 1 viruses appear to be highly heterogeneous (2, 23, 34) . Identification of heterogeneous VP7 type 1 strains and accumulation of additional nucleotide sequence data will be important in assessing the extent of genetic and antigenic variation in field strains of rotaviruses. Such molecular epidemiology studies of strains collected in specific areas will permit determination of whether there are accumulations of amino acid changes over time in antigenic sites and whether these eventually lead to the production of a new serotype and become problematic in successful vaccine development.
Our results also point out the need to use several MAbs in epitope-blocking assays to measure VP7 type 1-specific immune responses (15, 29 
